Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for Brown Adipose Tissue Activation in Cancer
NCT05779514Unknown
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mirabegron in cancer, sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Growth of brown adipose tissue at 28 days. Status: unknown.
02
Drugs
mirabegron
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05779514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05779514.